Department of Pathophysiology and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Allergol Int. 2013 Dec;62(4):503-11. doi: 10.2332/allergolint.13-OA-0536. Epub 2013 Oct 25.
Non-steroidal anti-inflammatory drugs (NSAIDs), especially aspirin, and food additives (FAs) may exacerbate allergic symptoms in patients with chronic idiopathic urticaria and food-dependent exercise-induced anaphylaxis (FDEIA). Augmentation of histamine release from human mast cells and basophils by those substances is speculated to be the cause of exacerbated allergic symptoms. We sought to investigate the mechanism of action of aspirin on IgE-mediated histamine release.
The effects of NSAIDs, FAs or cyclooxygenase (COX) inhibitors on histamine release from human basophils concentrated by gravity separation were evaluated.
Benzoate and tartrazine, which have no COX inhibitory activity, augmented histamine release from basophils similar to aspirin. In contrast, ibuprofen, meloxicam, FR122047 and NS-398, which have COX inhibitory activity, did not affect histamine release. These results indicate that the augmentation of histamine release by aspirin is not due to COX inhibition. It was observed that aspirin augmented histamine release from human basophils only when specifically activated by anti-IgE antibodies, but not by A23187 or formyl-methionyl-leucyl-phenylalanine. When the IgE receptor signaling pathway was activated, aspirin increased the phosphorylation of Syk. Moreover, patients with chronic urticaria and FDEIA tended to be more sensitive to aspirin as regards the augmentation of histamine release, compared with healthy controls.
Aspirin enhanced histamine release from basophils via increased Syk kinase activation, and that the augmentation of histamine release by NSAIDs or FAs may be one possible cause of worsening symptoms in patients with chronic urticaria and FDEIA.
非甾体抗炎药(NSAIDs),尤其是阿司匹林,以及食品添加剂(FAs),可能会使慢性特发性荨麻疹和食物依赖运动诱发过敏反应(FDEIA)患者的过敏症状恶化。推测这些物质会增强人肥大细胞和嗜碱性粒细胞释放组胺,从而导致过敏症状恶化。我们试图研究阿司匹林对 IgE 介导的组胺释放的作用机制。
评估 NSAIDs、FA 或环氧化酶(COX)抑制剂对重力分离浓缩的人嗜碱性粒细胞释放组胺的影响。
没有 COX 抑制活性的苯甲酸盐和酒石黄增强了嗜碱性粒细胞释放组胺,与阿司匹林相似。相比之下,具有 COX 抑制活性的布洛芬、美洛昔康、FR122047 和 NS-398 并不影响组胺释放。这些结果表明,阿司匹林增强组胺释放不是由于 COX 抑制。观察到只有当抗 IgE 抗体特异性激活时,阿司匹林才会增强人嗜碱性粒细胞释放组胺,而不是通过 A23187 或甲酰基-甲硫氨酸-亮氨酸-苯丙氨酸。当 IgE 受体信号通路被激活时,阿司匹林会增加 Syk 的磷酸化。此外,与健康对照组相比,慢性荨麻疹和 FDEIA 患者对阿司匹林增强组胺释放的敏感性更高。
阿司匹林通过增加 Syk 激酶的激活来增强嗜碱性粒细胞释放组胺,而 NSAIDs 或 FA 增强组胺释放可能是慢性荨麻疹和 FDEIA 患者症状恶化的一个可能原因。